(2S,4R)-tert-butyl 2-((3S)-1-(cyclopropylamino)-2-hydroxy-1-oxohexan-3-ylcarbamoyl)-4-(2-(pyridin-2-yl)thieno[3,2-d]pyrimidin-4-yloxy)pyrrolidine-1-carboxylate | 1035377-54-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4R)-tert-butyl 2-((3S)-1-(cyclopropylamino)-2-hydroxy-1-oxohexan-3-ylcarbamoyl)-4-(2-(pyridin-2-yl)thieno[3,2-d]pyrimidin-4-yloxy)pyrrolidine-1-carboxylate
• 英文别名: tert-butyl (2S,4R)-2-[[(3S)-1-(cyclopropylamino)-2-hydroxy-1-oxohexan-3-yl]carbamoyl]-4-(2-pyridin-2-ylthieno[3,2-d]pyrimidin-4-yl)oxypyrrolidine-1-carboxylate
• CAS: 1035377-54-8
• 化学式: C₃₀H₃₈N₆O₆S
• 分子量: 610.734
• InChiKey: DASUYBIXGXVCHF-NPGVOTQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  43
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  184
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• HCV INHIBITORS
  申请人：Green Michael J.

  公开号：US20080161254A1

  公开（公告）日：2008-07-03

  The present invention is directed to compounds that are antiviral agents. Specifically, the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及作为抗病毒剂的化合物。具体而言，本发明的化合物能抑制HCV的复制，因此在治疗丙型肝炎感染中非常有用。本发明还涉及包含这些化合物的药物组合物以及制备这些化合物的过程。
• [EN] HCV INHIBITORS<br/>[FR] INHIBITEURS DU VHC
  申请人：VIROBAY INC

  公开号：WO2008086053A1

  公开（公告）日：2008-07-17

  [EN] The present invention is directed to compounds that are antiviral agents. Specifically, the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
  [FR] La présente invention concerne des composés qui sont des agents antiviraux. Plus précisément, les composés selon l'invention inhibent la réplication du VHC et sont donc utiles pour traiter les infections par le virus de l'hépatite C. La présente invention concerne également des compositions pharmaceutiques contenant lesdits composés et des procédés de préparation associés.